WARREN, N.J. – June 18, 2018 – Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The code, Q9994, is effective July 1, 2018. CMS has instructed Medicare Administrative Contractors to add Q9994 to the relevant code set as of that date.